2025 India Cancer Immunotherapy Drug Discovery Outsourcing Market Revenue Opportunities Report
Description
The 2025 India Cancer Immunotherapy Drug Discovery Outsourcing Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Immunotherapy Drug Discovery Outsourcing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Cancer Immunotherapy Drug Discovery Outsourcing Market in India include Aragen Life Sciences Limited, Syngene International Limited, GenScript Biotech Corporation, and Biocon (via its spinout Bicara Therapeutics). Aragen and Syngene are major Indian Contract Research Organizations (CROs) providing outsourced drug discovery and development services with strong oncology and immunotherapy focus, supporting global pharma pipelines including cancer immunotherapy projects. GenScript Biotech is a global biotech service provider with capabilities in biologics and cell therapy discovery, essential for immunotherapies. Biocon’s spinout, Bicara Therapeutics, is developing innovative bifunctional antibodies for solid tumors and has raised substantial funding to enhance its pipeline and clinical programs in cancer immunotherapy, linking Indian innovation with global markets.
India's cancer immunotherapy market is growing rapidly, driven by CROs and CDMOs expanding service offerings from generics to innovative biologics and personalized medicines, supported by a skilled talent pool and increasing R&D capabilities. This growth is further fueled by rising investments in immunotherapy trials and manufacturing infrastructure by these companies to meet the growing demand within India and globally. Initiatives like the National Cancer Grid also demonstrate coordinated efforts to improve access to high-quality oncology drugs, facilitating collaborations with major drug discovery and service providers active in the immunotherapy domain.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Immunotherapy Drug Discovery Outsourcing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Cancer Immunotherapy Drug Discovery Outsourcing Market in India include Aragen Life Sciences Limited, Syngene International Limited, GenScript Biotech Corporation, and Biocon (via its spinout Bicara Therapeutics). Aragen and Syngene are major Indian Contract Research Organizations (CROs) providing outsourced drug discovery and development services with strong oncology and immunotherapy focus, supporting global pharma pipelines including cancer immunotherapy projects. GenScript Biotech is a global biotech service provider with capabilities in biologics and cell therapy discovery, essential for immunotherapies. Biocon’s spinout, Bicara Therapeutics, is developing innovative bifunctional antibodies for solid tumors and has raised substantial funding to enhance its pipeline and clinical programs in cancer immunotherapy, linking Indian innovation with global markets.
India's cancer immunotherapy market is growing rapidly, driven by CROs and CDMOs expanding service offerings from generics to innovative biologics and personalized medicines, supported by a skilled talent pool and increasing R&D capabilities. This growth is further fueled by rising investments in immunotherapy trials and manufacturing infrastructure by these companies to meet the growing demand within India and globally. Initiatives like the National Cancer Grid also demonstrate coordinated efforts to improve access to high-quality oncology drugs, facilitating collaborations with major drug discovery and service providers active in the immunotherapy domain.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
